Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05669313
Other study ID # Hypoth.Acidosis.Rivarox.ROTEM
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 4, 2022
Est. completion date November 10, 2022

Study information

Verified date February 2023
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rivaroxaban, a non-vitamin K oral anticoagulants, is increasingly used to prevent stroke in patients with atrium fibrillation. It has previously been demonstrated that a point-of-care coagulation instrument (ROTEM) can detect the effects of rivaroxaban. Further, the ROTEM instrument can also detect the effects of hypothermia and acidosis. Given that trauma induced coagulopathy is enhanced by both hypothermia, acidosis and rivaroxaban, the investigators want to investigate any synergistic effects between hypothermia or acidosis and rivaroxaban. In an attempt to do so the investigators designed the current experimental study with the purpose to investigate the effects of rivaroxaban together with hypothermia or acidosis using the ROTEM assay EXTEM. The hypothesis is that a synergistic prolongation of hypothermia or acidosis and rivaroxaban can be detected in the initiation of clot formation demonstrated in the primary outcome variable, clotting time of the ROTEM assay EXTEM. Secondary outcome variables include direct effect on clotting time and direct and synergistic effects on clot formation time and alfa angle of hypothermia and acidosis detected in the ROTEM assay EXTEM.


Description:

Non-vitamin K oral anticoagulants (NOACs) are widely used as prophylaxis against ischaemic stroke in patients with atrial fibrillation and have replaced vitamin K antagonists (VKA) in many case. Compared to the latter they have demonstrated reduced incidence of stroke, all-cause mortality, and a reduced risk of bleeding, except for gastrointestinal bleeding. According to guidelines from the European Society of Cardiology it is recommended that patients with atrial fibrillation (AF) and adequate CHA¬2DS2-VASc score (2 for men and 3 for women) preferentially are treated with NOAC rather than VKA, except in cases with significant mitral stenosis or mechanical heart valves. Both the prevalence of patients with AF and of patients treated with NOAC have increased in the last decade. The NOACs available in clinical practice include one thrombin inhibitor (dabigatran) and three factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) [3]. These drugs drive a patient's blood further from clotting toward bleeding, and managing this tendency is important for clinicians during haemorrhage or coagulopathy, which both occur e.g., in the setting of trauma. Trauma is a significant cause of mortality worldwide and among patients suffering from traumatic injuries the leading cause of preventable death is uncontrolled bleeding. Coagulopathy has been shown to contribute to bleeding in as many as one third of trauma cases, predicting organ failure and mortality. This trauma induced coagulopathy (TIC) is associated with hypothermia and acidosis. To prevent further coagulopathy current trauma guidelines recommend that both body temperature and pH are kept within normal reference range. Coagulopathy, hypothermia, and acidosis have collectively come to be known as the 'lethal triad'. For trauma patients, hypothermia is associated with larger usage of blood products and increased mortality/morbidity. How hypothermia affects haemostasis and blood loss has been investigated in several studies. Hypothermia has been shown to worsen the function of secondary haemostasis through temporary reduction of fibrinogen synthesis and inhibition of the initiation phase of thrombin generation. Hypothermia and acidosis often coexist and body temperatures of less than 35 degrees Celsius have been shown to correlate with acidosis. The effects of hypothermia and acidosis on whole blood coagulation in vitro, have previously been studied using Rotational thromboelastometry (ROTEM). For hypothermia, a significant increase in coagulation time (CT) and clot formation time (CFT) was observed, while acidosis alone did not produce these significant effects. Interestingly however, combining acidosis with hypothermia worsened the effects of the latter, providing increases in CT and CFT at higher temperatures, and a synergistic effect between acidosis and hypothermia could be demonstrated. The ROTEM assay EXTEM has previously been shown to be more sensitive to elevated concentrations of NOAC in blood compared with other ROTEM assays, with a demonstrated linear relationship between increasing concentrations of NOAC and prolonged clotting time (CT). In summary, the EXTEM-assay can detect the effect of rivaroxaban as well as effects of acidosis and hypothermia. However, to the best of the investigators knowledge the possibility of any synergistic effects of acidosis or hypothermia together with NOACs on the EXTEM-assay has never been explored. Given the increased prevalence of patients treated with NOAC and the importance of acidosis and hypothermia in critical bleeding the investigators designed the current experimental study with the purpose to investigate the effects of Rivaroxaban together with hypothermia or acidosis using the ROTEM assay EXTEM. The hypothesis is that a synergistic prolongation of hypothermia or acidosis and rivaroxaban can be detected in the initiation of clot formation demonstrated in the primary outcome variable, CT of the ROTEM assay EXTEM. Secondary outcome variables include direct effect on CT and direct and synergistic effects on CFT and AA of hypothermia and acidosis detected in the ROTEM assay EXTEM. Methods Adult patients >18 years of age, reporting to the emergency department during office hours at Skåne University Hospital Lund, Sweden that are planned for rivaroxaban treatment will be included. Baseline blood samples will be taken prior to the first dose of rivaroxaban (15 mg) and a second set of blood samples will be taken at a follow up visit the next day after two doses of rivaroxaban had been taken, the later dose being taken by the patient the morning of the follow up visit and thus ensuring sampling within one half-life of rivaroxaban. On both occasions venous blood will be drawn in 2.7 ml tubes containing 0.109 M citrate (BD Vacutainer Systems, Plymouth, UK) from an antecubital vein. At the follow up visit all patients will be asked for compliance to the rivaroxaban medication and were excluded if rivaroxaban had not been taken as prescribed. Upon the second visit a blood sample for analysis of rivaroxaban concentration wil be taken (ref. range peak value: 20 - 540 µg/L). All laboratory samples will be analysed at the accredited laboratories at Skåne University Hospital Lund or Malmö. Immediately after blood sampling, citrate blood will be transferred to 1.5 ml plastic test tubes (Sarstedt, Micro tube 1.5 ml, Sarstedt AG & Co. KG, Nümbrecht, Germany) and divided in one temperature group and one acidosis group, each consisting of four vials. The temperature group vials will be incubated for 20 minutes at their target goal temperatures of 28, 33, 37, and 40 degrees Celsius. The acidosis group will be incubated at 37 degrees Celsius and mixed with 15 µl of hydrochloric acid (HCl) at concentrations of 0.15 µM, 0.10 µM, 0.05 µM, or sterile water. Titration with the different concentrations of HCl will be tested prior to the current study using blood from healthy volunteers, with the goal of reaching the clinically relevant, pre-defined pH levels of 6.80, 7.00, and 7.20. After the addition of hydrochloric acid and sterile water the pH in each tube was measured using a pH-meter (Testo, Testo 230 pH/Temperature Meter, Testo SE & Co. KGaA, Lenzkirch, Germany). All tests were performed within four hours of drawing blood. After incubation at different temperatures and the addition of HCl/sterile water, all tests will be analysed using one of two machines: the acidosis group using ROTEM using the EXTEM assay. Clotting time (CT), Alpha angle (AA), and Clot formation time (CFT) will be registered.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date November 10, 2022
Est. primary completion date November 10, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients = 18 years old - any indication for starting treatment with rivaroxaban Exclusion Criteria: - recent medication, within the last month, with anticoagulating medication including Vitamin K antagonists and non-vitamin K antagonists, platelet inhibitors (not acetylsalicylic acid), non-steroidal anti-inflammatory drugs - previously diagnosed coagulopathy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rivaroxaban 15 MG
Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling

Locations

Country Name City State
Sweden Skåne University Hospital Lund Skåne

Sponsors (1)

Lead Sponsor Collaborator
Thomas Kander

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clotting time of the ROTEM assay EXTEM Measured in seconds From inclusion to the day after inclusion when the second blood sample was taken
Secondary Clot formation time of the ROTEM assay EXTEM Measured in seconds From inclusion to the day after inclusion when the second blood sample was taken
Secondary Alpha Angle of the ROTEM assay EXTEM Measured in degrees of the slope of the Temogram From inclusion to the day after inclusion when the second blood sample was taken
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Terminated NCT03781817 - Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures Phase 4
Completed NCT04342416 - Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women N/A
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Recruiting NCT04725721 - Testing FIRST in Youth Outpatient Psychotherapy N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT03696563 - FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS N/A
Withdrawn NCT03249129 - Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Completed NCT02240732 - Surgical Tourniquets and Cerebral Emboli N/A
Completed NCT02227979 - Effects of PURPLE Cry Intervention N/A
Withdrawn NCT01169025 - Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT03112304 - Child STEPS for Youth Mental Health in Maine Sustainability N/A
Completed NCT01475344 - Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) Phase 1/Phase 2
Completed NCT01201863 - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Phase 4
Completed NCT01210417 - Trauma Heart to Arm Time N/A
Completed NCT01426711 - Critical Care Excellence in Sepsis and Trauma